Press Releases
LOS ANGELES, June 1, 2024 /PRNewswire/ -- Vincent Todd is pleased to announce the introduction of generative agriculture firm Todd Agriscience. Capitalizing on the Founder's collective experience partnering in and building small scale organic and biodynamic farms, along with Todd's global reach and unrivaled social influence, the firm will guide management strategies in growth-oriented, market-leading organic and biodynamic farms. Todd Agriscience's primary focus is... (continue reading...)
- Total sales up 12% in May; YTD total sales increase 2%
- Best May for IONIQ 5, IONIQ 6, Tucson HEV, Santa Fe HEV, Palisade and Santa Cruz
- Hyundai May retail sales up 9% YOY; Volume led by Palisade, IONIQ 5 and Santa Fe HEV
- May EV sales up 42% YOY
FOUNTAIN VALLEY, Calif., June 1, 2024 /PRNewswire/ -- Hyundai Motor America reported total May sales of 78,485 units, a 12% increase compared with May 2023. Hyundai set total sales records in May for IONIQ 5 (+82%), IONIQ 6... (continue reading...)
An Innovative Line of Professional Cosmeceutical Formulas Designed To Help People "Rewind Time" on their Skin
BEVERLY HILLS, Calif., June 1, 2024 /PRNewswire/ -- Beverly Hills MD®, the cutting-edge skincare line created by renowned plastic surgeons Dr. John Layke and Dr. Payman Danielpour, is celebrating its 10th anniversary. Founded in 2014 by Dr. Layke and Dr. Danielpour, who co-founded the Beverly Hills Plastic Surgery Group, Beverly Hills MD emerged from their... (continue reading...)
Collaboration advances Cancer Moonshot call to empower patients, reduce duplication
CHICAGO, June 1, 2024 /PRNewswire/ -- The American Cancer Society (ACS) and the American Society of Clinical Oncology (ASCO) today announced an expanded collaboration to make it simpler for patients to find authoritative cancer information online. The partnership between ASCO, the leading organization for cancer care providers, and ACS, the leading patient education, support, and... (continue reading...)
Ankyra Therapeutics will provide an update on the status of the ANK-101 Phase 1 ANCHOR clinical trial at ASCO 2024 and has received approval by FDA and Health Canada to amend the Phase I study to include patients with solid tumors in visceral organs
CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Ankyra Therapeutics, a clinical-stage oncology company developing anchored immunotherapies to improve the therapeutic window for immuno-oncology drugs, announced today that it is... (continue reading...)
More Press Releases
View Older Stories-
Sally Hansen® and GLAAD Reprise Their Partnership for the 6th Year With a Launch That Celebrates the LGBTQ+ Community
-
Werewolf Therapeutics to Present Data from Ongoing Phase 1/1b Clinical Trial of WTX-124 as Monotherapy and in Combination with Pembrolizumab in Solid Tumors
-
ClearPoint Neuro Announces Full Market Release of SmartFrame OR™ and ClearPoint PRISM® 3T Laser Therapy System
-
5 Ways BPO Services Can Improve Your Business Operations
-
Amazed by these incredible facts about the yellow diamond
-
Maximizing Efficiency: The Role of Content Moderation Services
-
Wisconsin Top Performing Stocks
-
FSLY INVESTOR DEADLINE: Robbins Geller Rudman & Dowd LLP Announces that Fastly, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit
-
Ultimovacs Announces Poster Presentation at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting
-
Y-mAbs Announces Publication of Preclinical GD2-SADA Data at 2024 ASCO Annual Meeting
-
Nuvation Bio Announces Data from Pivotal Phase 2 TRUST-I Study of its Investigational ROS1 Inhibitor, Taletrectinib, are Published in the Journal of Clinical Oncology and Reported at 2024 ASCO Annual
-
Jazz Pharmaceuticals Presents Overall Survival and Longer Follow-Up Data from HERIZON-BTC-01 Trial Evaluating Zanidatamab in Previously Treated HER2-Positive Biliary Tract Cancer at ASCO 2024
-
Y-mAbs Announces New Interim Analysis of Phase 2 Data for Naxitamab at 2024 ASCO Annual Meeting
-
Ivonescimab Manuscript for HARMONi-A Clinical Trial Results Published in JAMA
-
Immunocan Launches Innovative Alpaca-derived Nanobody Discovery Platform: ImmuAlpaca® Mouse
-
James Avery Artisan Jewelry Opens New Store at Westover Marketplace
-
Gilead and Arcus Announce Anti-TIGIT Domvanalimab Plus Zimberelimab and Chemotherapy Exceeded One Year of Median Progression-Free Survival as a First-Line Treatment for Upper GI Cancers
-
TiumBio Presents Phase 1b Interim Results for TU2218 in Combination with Pembrolizumab at ASCO 2024 Annual Meeting
-
Takeda and Pfizer Announce Four-Year Results from Positive Phase 3 HD21 Trial of Additional ADCETRIS® (brentuximab vedotin) Combination in Frontline Hodgkin Lymphoma
-
Pfizer’s ADCETRIS® Regimen Produces Clinically Meaningful Improvement in Overall Survival in Patients with Relapsed/Refractory Diffuse Large B-cell Lymphoma (DLBCL)
-
Updated Data from the Phase 1/2 Study of Olomorasib in KRAS G12C-Mutant Advanced Solid Tumors Presented at the 2024 ASCO® Annual Meeting
-
BALEAF & SOJOS to host "Summer it up" summer fashion extravaganza!
-
Boehringer Ingelheim's COPD and asthma inhalers are now available for $35 a month for eligible patients
-
KRAZATI (adagrasib) Demonstrated Statistically Significant Improvement in Progression-Free Survival in Patients with Pretreated Locally Advanced or Metastatic KRASG12C-Mutated Non-Small Cell Lung Canc
-
Massive Bio to Unveil Drug Utilization Optimizer (DUO) at ASCO Annual Meeting 2024
-
OkayCoin CEO Releases Key Strategies to Maximize Investor Returns on Staking Platform
-
Accutar Biotechnology Presents Phase 1 Data of AC699 Monotherapy in Patients with ER+ / HER2- Breast Cancer at ASCO 2024
-
Purple Biotech Announces Positive Late-Breaking Interim Randomized Phase 2 Data at ASCO 2024 Demonstrating CM24 Improved Overall Survival and other Efficacy Endpoints in Pancreatic Cancer
-
Molecular Partners Presents Positive Data From Completed Phase 1 Trial Of MP0317 (FAP X CD40 DARPin) Monotherapy In Patients With Advanced Solid Tumors At ASCO 2024
-
CryptoHeap Targets Top Position in Crypto Staking Industry Before Bull Run Concludes
-
Immunocore presents KIMMTRAK clinical data demonstrating that patients with stable disease and confirmed tumor reduction have similar clinical outcomes to patients with partial response
-
Kymera Therapeutics Presents New Clinical Data from Ongoing Phase 1 Trial of MDM2 Degrader KT-253 at ASCO Annual Meeting
-
ENPH INVESTOR NOTICE: Robbins Geller Rudman & Dowd LLP Announces that Enphase Energy, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit
-
Gruvtype features de Buyer Products in Global Culinary Adventure with Free "Street, Beach & Sky" Preview Cookbook
-
Ivonescimab in Combination with Chemotherapy Approved in China by NMPA for 2L+ EGFRm NSCLC based on HARMONi-A Clinical Trial: Positive Trend Observed in Overall Survival towards Ivonescimab Plus Chemo
-
Cullinan Therapeutics Announces Positive Initial Data from Pivotal Phase 2b REZILIENT1 Study of Zipalertinib
-
Horizon Wealth Donates $3 Million for Brazil's Post-Disaster Reconstruction
-
Eurasian Capital Participates in the Third ICPAC Mediterranean Financial Summit: Exploring the Future Frontiers of Finance
-
XAR and Salus Join Forces to Build zkLogin 'Hikari': The Final Step to Mass Adoption on Starknet
-
Brandmydispo Continues to Innovate the Custom Mylar Bag Space
-
ZEEKR Announces May 2024 Delivery Update
-
Pamela Dowell's newly released "Saucey's Adventure" is a delightful adventure of a young unicorn in an unknown land.
-
VENTYX SHAREHOLDER REMINDER: BFA Law Reminds Ventyx Biosciences, Inc. (NASDAQ: VTYX) Shareholders to Contact the Firm About Ongoing Investigation
-
SQSP (NYSE) REMINDER: BFA Law Reminds Squarespace Shareholders to Inquire About Ongoing Investigation into the $44 Buyout Offer
-
SPT (NYSE) FRAUD ALERT: Sprout Social, Inc. Investors who Lost Money when Stock Plummeted 40% are Encouraged to Contact BFA Law about Upcoming Deadline
-
PATH (NYSE) INVESTOR ALERT: UiPath, Inc. Investigated for Securities Fraud After 34% Stock Drop, Contact BFA Law if You Suffered Losses
-
CERE (NASDAQ) REMINDER: BFA Law Reminds Cerevel Shareholders to Inquire About Ongoing Investigation into the $45 Merger Offer
-
CAE (NYSE) INVESTOR ALERT: CAE, Inc. Investigated for Securities Fraud from Impairment Charges, Contact BFA Law if You Suffered Losses
-
BIIB (NASDAQ) FRAUD ALERT: Biogen Inc. Investors who Lost Money are Encouraged to Contact BFA Law about Upcoming Legal Deadline
-
NIO Inc. Provides May 2024 Delivery Update